ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE

被引：2
|
作者：
Hatzikou, M. [1 ]
Rombopoulos, G. [1 ]
Yfantopoulos, J. [2 ]
机构：
[1] Novartis Hellas, Metamorfosis, Greece
[2] Univ Athens, Athens 11528, Greece
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1686
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A501 / A501
页数：1
相关论文
共 50 条
  • [41] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
    Gao, Lan
    Zhao, Fei-Li
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
  • [42] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
    Mueller-Wieland, Dirk
    Kellerer, Monika
    Cypryk, Katarzyna
    Skripova, Dasa
    Rohwedder, Katja
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Kurlyandskaya, Raisa
    Sjostrom, C. David
    Jacob, Stephan
    Seufert, Jochen
    Dronamraju, Nalina
    Csomos, Katalin
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607
  • [43] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Gao, L.
    Li, S. C.
    VALUE IN HEALTH, 2012, 15 (07) : A663 - A663
  • [44] Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdravkovic, Milan
    Matthews, David
    PRIMARY CARE DIABETES, 2010, 4 (02) : 113 - 117
  • [45] Mechanism Based Pharmacokinetic Pharmacodynamic Modeling of Vildagliptin as an Add-on to Metformin for Subjects with Type 2 Diabetes
    Eftekhari, Marziyeh
    Vahidi, Omid
    CMES-COMPUTER MODELING IN ENGINEERING & SCIENCES, 2018, 114 (02): : 153 - 171
  • [46] Empaglifl ozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 4 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Robert, Knut
    Toorawa, Andersen
    Woerle, Hans J.
    Salsali, Afshin
    DIABETES, 2016, 65 : A47 - A48
  • [47] ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL
    Brennan, A.
    Gillett, M.
    Duenas, A.
    VALUE IN HEALTH, 2008, 11 (06) : A501 - A501
  • [48] Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
    Mendez-del Villar, Miriam
    Martinez-Abundis, Esperanza
    Preciado-Marquez, Rafael O.
    Gonzalez-Ortiz, Manuel
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (02): : 188 - 192
  • [49] Add-on therapies to metformin for type 2 diabetes
    Shomali, Mansur
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 47 - 62
  • [50] Long-term efficacy and safety of add-on therapy of vildagliptin in type 2 diabetes mellitus with insulin treatment
    Kanazawa, Ippei
    Tanaka, Ken-ichiro
    Notsu, Masakazu
    Tanaka, Sayuri
    Kiyohara, Nobuaki
    Koike, Sayo
    Yamane, Yuko
    Tada, Yuko
    Sasaki, Motofumi
    Yamauchi, Mika
    Sugimoto, Toshitsugu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S107 - S107
12345